Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with CDK4/6i and Endocrine Therapy in SNF1 Subtype Advanced Breast Cancer
NCT05949541Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in breast cancer, sponsored by Fudan University. Started Jul 2023; status: recruiting.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05949541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949541.